Bharat Immunologicals & Biologicals (BOM:524663) LT-Debt-to-Total-Asset: 0.02 (As of Sep. 2023)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:524663 Bharat Immunologicals & Biologicals Corp Ltd BOM:524663
4 GF Score
Price ₹15.40
View Full Analysis

What is Bharat Immunologicals & Biologicals LT-Debt-to-Total-Asset?

Bharat Immunologicals & Biologicals BOM:524663 +0.13% 4 LT-Debt-to-Total-Asset is 0.02 as of Sep. 2023. GuruFocus rates BOM:524663 with a GF Score™ of 4/100.

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. Bharat Immunologicals & Biologicals's long-term debt to total assests ratio for the quarter that ended in Sep. 2023 was 0.02.

Bharat Immunologicals & Biologicals's long-term debt to total assets ratio increased from Sep. 2022 (0.00) to Sep. 2023 (0.02). It may suggest that Bharat Immunologicals & Biologicals is progressively becoming more dependent on debt to grow their business.

Bharat Immunologicals & Biologicals  (BOM:524663) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

Bharat Immunologicals & Biologicals LT-Debt-to-Total-Asset Related Terms

Bharat Immunologicals & Biologicals LT-Debt-to-Total-Asset Historical Data

* Premium members only.

The historical data trend for Bharat Immunologicals & Biologicals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Bharat Immunologicals & Biologicals LT-Debt-to-Total-Asset Chart

Bharat Immunologicals & Biologicals Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
LT-Debt-to-Total-Asset
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Bharat Immunologicals & Biologicals Quarterly Data
Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23
LT-Debt-to-Total-Asset Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.02
BOM:524663
4GF Score
Bharat Immunologicals & Biologicals Corp Ltd BOM:524663
LT-Debt-to-Total-Asset is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Bharat Immunologicals & Biologicals LT-Debt-to-Total-Asset Calculation

Bharat Immunologicals & Biologicals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Mar. 2023 is calculated as

LT Debt to Total Assets (A: Mar. 2023 )=Long-Term Debt & Capital Lease Obligation (A: Mar. 2023 )/Total Assets (A: Mar. 2023 )
=0/1886.473
=0.00

Bharat Immunologicals & Biologicals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2023 is calculated as

LT Debt to Total Assets (Q: Sep. 2023 )=Long-Term Debt & Capital Lease Obligation (Q: Sep. 2023 )/Total Assets (Q: Sep. 2023 )
=35/1881.313
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about LT-Debt-to-Total-Asset →
What does a LT-Debt-to-Total-Asset of 0.02 mean?
Bharat Immunologicals & Biologicals (BOM:524663) has a LT-Debt-to-Total-Asset of 0.02 as of Sep. 2023. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bharat Immunologicals & Biologicals and its competitors.
Is Bharat Immunologicals & Biologicals' LT-Debt-to-Total-Asset too high?
Bharat Immunologicals & Biologicals' current LT-Debt-to-Total-Asset is 0.02. Overall, Bharat Immunologicals & Biologicals has a GF Score™ of 4/100, reflecting its overall financial health beyond just this single metric.
How does Bharat Immunologicals & Biologicals' LT-Debt-to-Total-Asset compare to VRTX and REGN?
Bharat Immunologicals & Biologicals' LT-Debt-to-Total-Asset of 0.02 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good LT-Debt-to-Total-Asset for a Biotechnology company?
A good LT-Debt-to-Total-Asset depends on the Biotechnology industry context. However, LT-Debt-to-Total-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high LT-Debt-to-Total-Asset mean?
A high LT-Debt-to-Total-Asset can signal that a stock is expensive relative to its fundamentals. Long-term Debt to Total Asset ratio is the ratio of total long-term debt to total assets. View historical data on Bharat Immunologicals & Biologicals and its competitors. Bharat Immunologicals & Biologicals's current LT-Debt-to-Total-Asset is 0.02. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bharat Immunologicals & Biologicals stock overvalued right now?
Bharat Immunologicals & Biologicals (BOM:524663) has a current LT-Debt-to-Total-Asset of 0.02. The current LT-Debt-to-Total-Asset is 0.02. Bharat Immunologicals & Biologicals' overall GF Score™ is 4/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is LT-Debt-to-Total-Asset calculated?
LT-Debt-to-Total-Asset is calculated from a company's financial statements. For Bharat Immunologicals & Biologicals (BOM:524663), the current LT-Debt-to-Total-Asset is 0.02 as of Sep. 2023. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Bharat Immunologicals & Biologicals Business Description

Address Village Chola, BIBCOL, OPV Plant, Bulandshahar, UP, IND, 203203
Bharat Immunologicals & Biologicals Corp Ltd is an India-based biotechnology company. It primarily manufactures Oral polio vaccines. In addition, the company also manufactures zinc tablets, diarrhea management kits, and Ready to Use Therapeutic Food (RUTF). It also manufactures nutraceuticals and biological products for the treatment of health deficiencies and disorders. The firm is organized into three segments: Oral Polio Vaccine, Zinc Tablets, and BIB VIT, BIBSANIT. The group principally operates in India and generates the majority of its revenue from sales of Oral polio vaccines.
4GF Score

Get the complete analysis for BOM:524663

LT-Debt-to-Total-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹15.40
Price